Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM: lisocabtagene maraleucel versus standard of care in high-risk relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
NL-OMON52699Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 3 more comparing Standard of care with Breyanzi arm (2 arms). Primary endpoint: Event-free survival. Started Jun 2020; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Beyond the preview
Go deeper on NL-OMON52699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52699.